Ruane, Cunniff & Goldfarb L.P. Atai Life Sciences N.V. Transaction History
Ruane, Cunniff & Goldfarb L.P.
- $5.45 Billion
- Q3 2024
A detailed history of Ruane, Cunniff & Goldfarb L.P. transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Ruane, Cunniff & Goldfarb L.P. holds 42,112 shares of ATAI stock, worth $64,010. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,112
Previous 42,112
-0.0%
Holding current value
$64,010
Previous $56,000
14.29%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ATAI
# of Institutions
89Shares Held
12.4MCall Options Held
77.8KPut Options Held
50.3K-
Morgan Stanley New York, NY3.04MShares$4.62 Million0.0% of portfolio
-
Walleye Capital LLC Plymouth, MN2.26MShares$3.44 Million0.01% of portfolio
-
Black Rock Inc. New York, NY1.31MShares$1.99 Million0.0% of portfolio
-
Brown University719KShares$1.09 Million0.36% of portfolio
-
Round Table Services, LLC704KShares$1.07 Million0.46% of portfolio
About ATAI Life Sciences N.V.
- Ticker ATAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 165,875,008
- Market Cap $252M
- Description
- Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...